Tango Therapeutics (TNGX) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings or view top-rated stocks.

1 brokers have issued 1 year price targets for Tango Therapeutics' shares. Their TNGX share price forecasts range from $11.00 to $21.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 435.1% from the stock's current price.
View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts.

Tango Therapeutics' stock was trading at $7.25 at the beginning of 2023. Since then, TNGX stock has decreased by 58.8% and is now trading at $2.99.
View the best growth stocks for 2023 here.

Tango Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 1,820,000 shares, a drop of 18.0% from the April 30th total of 2,220,000 shares. Based on an average daily trading volume, of 166,100 shares, the short-interest ratio is currently 11.0 days. Currently, 3.6% of the shares of the company are short sold.
View Tango Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our TNGX earnings forecast.

Tango Therapeutics, Inc. (NASDAQ:TNGX) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The company had revenue of $5.77 million for the quarter, compared to analysts' expectations of $6.70 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 42.34% and a negative net margin of 446.26%.

ETFs with the largest weight of Tango Therapeutics (NASDAQ:TNGX) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS), Invesco Nasdaq Biotechnology ETF (IBBQ).

Tango Therapeutics trades on the NASDAQ under the ticker symbol "TNGX."

Tango Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (10.78%), BlackRock Inc. (4.00%), Geode Capital Management LLC (1.00%), State Street Corp (0.93%), Bank of New York Mellon Corp (0.16%) and Swiss National Bank (0.12%).
View institutional ownership trends.

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TNGX stock can currently be purchased for approximately $2.99.

Tango Therapeutics (NASDAQ:TNGX) has a market capitalization of $264.35 million and generates $24.86 million in revenue each year. The company earns $-108,180,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

Tango Therapeutics' mailing address is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.tangotx.com. The company can be reached via phone at 857-320-4900.